A Phase II, Multicenter, Adaptive-design Study to Assess the Safety and Efficacy of VM202RY Injected Via Percutaneous Transendocardial Route in Subjects With Acute Myocardial Infarction

Trial Profile

A Phase II, Multicenter, Adaptive-design Study to Assess the Safety and Efficacy of VM202RY Injected Via Percutaneous Transendocardial Route in Subjects With Acute Myocardial Infarction

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Donaperminogene seltoplasmid (Primary)
  • Indications Coronary artery disease; Ischaemic heart disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Jan 2018 Status changed from planning to recruiting.
    • 02 Aug 2016 According to a VM BioPharma media release, the Ministry of Food and Drug Safety in Korea (MFDS) has approved an Investigational New Drug (IND) application for VM202 for the treatment of ischaemic heart disease facilitating this trial.
    • 27 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top